Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication <it>in vitro </it>and provide a rationale to redesign antiretroviral treatment for feline AIDS

• Main Authors: Ciervo Alessandra, Barreca Maria, De Luca Laura, Matteucci Donatella, Ferro Stefania, Mancini Fabiola, Taglia Fabiana, Zabogli Elisa, D'Ostilio Daniela, Pistello Mauro, Savarino Andrea, Chimirri Alba, Ciccozzi Massimo, Bendinelli Mauro
• Format: Article
• Language: English
• Published: BMC 2007-10-01
• Series: Retrovirology
• Online Access: http://www.retrovirology.com/content/4/1/79

<p>Abstract</p> <p>Background</p> <p>Treatment of feline immunodeficiency virus (FIV) infection has been hampered by the absence of a specific combination antiretroviral treatment (ART). Integrase strand transfer inhibitors (INSTIs) are emerging as a promising new drug class for HIV-1 treatment, and we evaluated the possibility of inhibiting FIV replication using INSTIs.</p> <p>Methods</p> <p>Phylogenetic analysis of lentiviral integrase (IN) sequences was carried out using the PAUP* software. A theoretical three-dimensional structure of the FIV IN catalytic core domain (CCD) was obtained by homology modeling based on a crystal structure of HIV-1 IN CCD. The interaction of the transferred strand of viral DNA with the catalytic cavity of FIV IN was deduced from a crystal structure of a structurally similar transposase complexed with transposable DNA. Molecular docking simulations were conducted using a genetic algorithm (GOLD). Antiviral activity was tested in feline lymphoblastoid MBM cells acutely infected with the FIV Petaluma strain. Circular and total proviral DNA was quantified by real-time PCR.</p> <p>Results</p> <p>The calculated INSTI-binding sites were found to be nearly identical in FIV and HIV-1 IN CCDs. The close similarity of primate and feline lentivirus IN CCDs was also supported by phylogenetic analysis. In line with these bioinformatic analyses, FIV replication was efficiently inhibited in acutely infected cell cultures by three investigational INSTIs, designed for HIV-1 and belonging to different classes. Of note, the naphthyridine carboxamide INSTI, L-870,810 displayed an EC₅₀in the low nanomolar range. Inhibition of FIV integration <it>in situ </it>was shown by real-time PCR experiments that revealed accumulation of circular forms of FIV DNA within cells treated with L-870,810.</p> <p>Conclusion</p> <p>We report a drug class (other than nucleosidic reverse transcriptase inhibitors) that is capable of inhibiting FIV replication <it>in vitro</it>. The present study helped establish L-870,810, a compound successfully tested in human clinical trials, as one of the most potent anti-FIV agents ever tested <it>in vitro</it>. This finding may provide new avenues for treating FIV infection and contribute to the development of a small animal model mimicking the effects of ART in humans.</p>